StreetInsider.com News Articles

Valneva misses revenue estimates, reaffirms guidance; stock jumps

Thu, 20 Nov 2025 06:56:17 -0400

Investing.com -- Valneva reported nine-month revenue that missed analyst expectations but reaffirmed its full-year outlook.

The company’s shares jumped 6% in Paris after the report.

Valneva reported nine-month revenues of 127 million euros and product sales of 119.4 million euros, missing the 132.3 million consensus estimate cited by Kepler Cheuvreux.

Sales from Valneva’s Japanese encephalitis vaccine Ixiaro grew 12.5% to 74.3 million euros over the nine-month period, though the pace weakened sharply in the third quarter as the earlier catch-up effect faded and last year’s base became more demanding.

Dukoral remained stable at 21.5 million euros, while Ixchiq contributed 7.6 million

Valneva misses revenue estimates, reaffirms guidance; stock jumps

Thu, 20 Nov 2025 06:56:17 -0400

Investing.com -- Valneva reported nine-month revenue that missed analyst expectations but reaffirmed its full-year outlook.

The company’s shares jumped 6% in Paris after the report.

Valneva reported nine-month revenues of 127 million euros and product sales of 119.4 million euros, missing the 132.3 million consensus estimate cited by Kepler Cheuvreux.

Dukoral remained stable at 21.5 million euros, while Ixchiq contributed 7.6 million

Development funding of £4.9m secured for next stage of UK waste-to-jet fuel project from industry partners and Department for Transport

Mon, 18 Jun 2018 10:33:00 -0400

si-local-file:///var/storage/newsbody/2018/0618/14316144.html